Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Juan-Carlos Ruiz-CoboJordi LlanerasXavier FornsAdolfo Gallego MoyaIsabel Conde AmielAna ArencibíaMoises DiagoJavier García-SamaniegoJose CastelloteSusana LlerenaElisa Rodríguez-SeguelBeatriz MateosManuel RodríguezJose Miguel Rosales ZabalInmaculada FernándezJose Luis CallejaRosa María MorillasSilvia MontoliuRaúl Jesús AndradeEster Badia ArandaManuel Hernández GuerraCarlota Jimeno MatéJesús M González-SantiagoBeatriz de CuencaVanesa Bernal-MonterdeManuel DelgadoJuan Turnes VázquezSabela LensMaria Buti FerretPublished in: Alimentary pharmacology & therapeutics (2024)
SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs.